Cargando…

Shorter Hospital Stays and Lower Costs for Rivaroxaban Compared With Warfarin for Venous Thrombosis Admissions

BACKGROUND: Venous thromboembolism, including deep vein thrombosis and pulmonary embolism, results in a substantial healthcare system burden. This retrospective observational study compared hospital length of stay (LOS) and hospitalization costs for patients with venous thromboembolism treated with...

Descripción completa

Detalles Bibliográficos
Autores principales:	Margolis, Jay M., Deitelzweig, Steven, Kline, Jeffrey, Tran, Oth, Smith, David M., Bookhart, Brahim, Crivera, Concetta, Schein, Jeff
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2016
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5121479/ https://www.ncbi.nlm.nih.gov/pubmed/27792638 http://dx.doi.org/10.1161/JAHA.116.003788

Ejemplares similares

Effect of Rivaroxaban Versus Warfarin on Health Care Costs Among Nonvalvular Atrial Fibrillation Patients: Observations from Rivaroxaban Users and Matched Warfarin Users
por: Laliberté, François, et al.
Publicado: (2015)

Erratum to: Effect of Rivaroxaban Versus Warfarin on Health Care Costs Among Nonvalvular Atrial Fibrillation Patients: Observations from Rivaroxaban Users and Matched Warfarin Users
por: Laliberté, François, et al.
Publicado: (2015)

Clinical outcomes of prolonged anticoagulation with rivaroxaban after unprovoked venous thromboembolism
por: Berger, Jeffrey S., et al.
Publicado: (2017)

The Role of Warfarin and Rivaroxaban in the Treatment of Cerebral Venous Thrombosis
por: Fayyaz, Muniba, et al.
Publicado: (2019)

One-Year Adherence to Warfarin Treatment for Venous Thromboembolism in High-Risk Patients and Its Association with Long-term Risk of Recurrent Events
por: Chen, Shih-Yin, et al.
Publicado: (2013)

Healthcare Resource Utilization and Costs of Rivaroxaban Versus Warfarin Among Nonvalvular Atrial Fibrillation Patients with Obesity and Diabetes
por: Weir, Matthew R., et al.
Publicado: (2021)

Effectiveness and Safety of Rivaroxaban Versus Warfarin among Nonvalvular Atrial Fibrillation Patients with Concomitant Obstructive Sleep Apnea
por: Sood, Nitesh, et al.
Publicado: (2023)

Analysis of recanalization of deep venous thrombosis: a comparative study of patients treated with warfarin vs. rivaroxaban
por: Piati, Polyana Klomfass, et al.
Publicado: (2019)

Clinical and Economic Outcomes in Low-risk Pulmonary Embolism Patients Treated with Rivaroxaban versus Standard of Care
por: Peacock, W. Frank, et al.
Publicado: (2019)

Postthrombotic Syndrome in Patients Treated With Rivaroxaban or Warfarin for Venous Thromboembolism
por: Coleman, Craig I., et al.
Publicado: (2018)

Rivaroxaban for the treatment of cerebral venous thrombosis
por: Esmaeili, Sara, et al.
Publicado: (2021)

Healthcare Resource Utilization and Costs of Rivaroxaban Versus Warfarin Among Non-valvular Atrial Fibrillation (NVAF) Patients with Diabetes in a US Population
por: Berger, Jeffrey S., et al.
Publicado: (2023)

Use of oral rivaroxaban in cerebral venous thrombosis
por: Maqsood, Muhammad, et al.
Publicado: (2020)

Rivaroxaban Treatment for Warfarin-Refractory Thrombosis in a Patient with Hereditary Protein S Deficiency
por: Ameku, Koken, et al.
Publicado: (2018)

Predictors of Hospital Length of Stay among Patients with Low-risk Pulmonary Embolism
por: Wang, Li, et al.
Publicado: (2019)

Rivaroxaban vs. warfarin for the treatment and prevention of venous thromboembolism: A meta-analysis
por: Liu, Zhuang, et al.
Publicado: (2023)

Validation of venous thromboembolism diagnoses in patients receiving rivaroxaban or warfarin in The Health Improvement Network
por: Ruigómez, Ana, et al.
Publicado: (2020)

Recurrent hospitalization and healthcare resource use among patients with deep vein thrombosis and pulmonary embolism: findings from a multi-payer analysis
por: Lang, Kathleen, et al.
Publicado: (2014)

Comparison of Enoxaparin and Rivaroxaban in the Prophylaxis of Deep Venous Thrombosis in Arthroplasty
por: Çiçek, Necati, et al.
Publicado: (2021)

Impact of Once-Daily Versus Twice-Daily Dosing Frequency on Adherence to Chronic Medications among Patients with Venous Thromboembolism
por: Laliberté, François, et al.
Publicado: (2013)

A Cost Effectiveness Analysis of Rivaroxaban Compared to Warfarin for Deep Vein Thrombosis (DVT) Treatment in Ethiopia
por: Derseh, Manaye Tamrie, et al.
Publicado: (2021)

Evaluation of rivaroxaban versus warfarin for the treatment of cerebral vein thrombosis: A case-control blinded study
por: Khorvash, Fariborz, et al.
Publicado: (2021)

Treatment of central venous catheter‐associated deep venous thrombosis in cancer patients with rivaroxaban
por: Laube, Eva S., et al.
Publicado: (2016)

Current practice patterns and patient persistence with anticoagulant treatments for cancer‐associated thrombosis
por: Khorana, Alok A., et al.
Publicado: (2017)

Outcomes associated with comorbid atrial fibrillation and heart failure in medicare beneficiaries with acute coronary syndrome
por: Chen, Shih-Yin, et al.
Publicado: (2014)

Attitudes toward anticoagulant treatment among nonvalvular atrial fibrillation patients at high risk of stroke and low risk of bleed
por: Crivera, Concetta, et al.
Publicado: (2016)

Quantitative Systems Pharmacology Model-Based Predictions of Clinical Endpoints to Optimize Warfarin and Rivaroxaban Anti-Thrombosis Therapy
por: Hartmann, Sonja, et al.
Publicado: (2020)

Cost-effectiveness of rivaroxaban compared with enoxaparin plus warfarin for the treatment of hospitalised acute deep vein thrombosis in China
por: Yang, Li, et al.
Publicado: (2020)

Anticoagulation with warfarin and rivaroxaban ameliorates experimental autoimmune encephalomyelitis
por: Stolz, Leonie, et al.
Publicado: (2017)

Rivaroxaban versus warfarin for the management of left ventricle thrombus
por: Albabtain, Monirah A., et al.
Publicado: (2021)

Venous thrombosis recurrence risk according to warfarin versus direct oral anticoagulants for the secondary prevention of venous thrombosis
por: Zakai, Neil A., et al.
Publicado: (2021)

Switching from rivaroxaban to warfarin: an open label pharmacodynamic study in healthy subjects
por: Moore, Kenneth Todd, et al.
Publicado: (2015)

Effectiveness and safety of anticoagulants for the treatment of venous thromboembolism in patients with cancer
por: Streiff, Michael B., et al.
Publicado: (2018)

Successful Treatment and Secondary Prevention of Venous Thrombosis Secondary to Behçet Disease with Rivaroxaban
por: Boban, Ana, et al.
Publicado: (2016)

An Observational Study to Evaluate the Effectiveness of Rivaroxaban in the Management of Cerebral Venous Sinus Thrombosis
por: Fatima, Meraj, et al.
Publicado: (2021)

Successful use of rivaroxaban in postoperative deep vein thrombosis of the lower limb following instability with warfarin: a case report
por: Schiavoni, Mario, et al.
Publicado: (2016)

Risk of Gastrointestinal Bleeding with Rivaroxaban: A Comparative Study with Warfarin
por: Sherid, Muhammed, et al.
Publicado: (2016)

Safety of apixaban and rivaroxaban compared to warfarin after cardiac surgery
por: Naik, Kushal D., et al.
Publicado: (2022)

All-Cause and Potentially Disease-Related Health Care Costs Associated with Venous Thromboembolism in Commercial, Medicare, and Medicaid Beneficiaries
por: Lefebvre, Patrick, et al.
Publicado: (2012)

Length of Stay Comparison between Rivaroxaban and Warfarin in the Treatment of Pulmonary Embolism: Results from a Real-World Observational Cohort Study
por: Roberts, Kirsten M., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_jmpbc80433flio1m1jdo72duib